Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2023-03-06 00:00:00 ET · period of report 2023-03-02 · accession 0001628280-23-006532 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-06 | 2023-03-02 | AUPH | Donley Matthew Maxwell | EVP, Ops, Strategy | A - Grant | — | +271.1K | 403.1K | +205% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | A | A | 271,134 | — | 403,141 | D | — | — | (F1) Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F3) The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 271,134 newly awarded RSUs, 104,080 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 27,927 shares of common stock. On March 2, 2023, 34,693 of Prior RSUs vested and 69,387 of Prior RSUs remained unvested. |